See more : China Resources and Environment Co.,Ltd. (600217.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Nevro Corp. (NVRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nevro Corp., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Daiyang Metal Co., Ltd. (009190.KS) Income Statement Analysis – Financial Results
- ATI Physical Therapy, Inc. (ATIP) Income Statement Analysis – Financial Results
- Botanix Pharmaceuticals Limited (BOT.AX) Income Statement Analysis – Financial Results
- Frasers Group plc (FRAS.L) Income Statement Analysis – Financial Results
- Yihai International Holding Ltd. (YNNHF) Income Statement Analysis – Financial Results
Nevro Corp. (NVRO)
About Nevro Corp.
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 425.17M | 406.37M | 386.91M | 362.05M | 390.26M | 387.29M | 326.67M | 228.50M | 69.61M | 32.57M | 23.50M | 18.15M |
| Cost of Revenue | 135.11M | 130.00M | 120.86M | 112.15M | 121.91M | 113.97M | 98.98M | 75.43M | 28.12M | 11.28M | 9.47M | 7.53M |
| Gross Profit | 290.06M | 276.37M | 266.04M | 249.90M | 268.35M | 273.32M | 227.69M | 153.07M | 41.49M | 21.30M | 14.03M | 10.62M |
| Gross Profit Ratio | 68.22% | 68.01% | 68.76% | 69.02% | 68.76% | 70.57% | 69.70% | 66.99% | 59.60% | 65.38% | 59.69% | 58.53% |
| Research & Development | 54.42M | 53.07M | 47.67M | 45.60M | 59.02M | 48.46M | 37.56M | 33.73M | 21.38M | 19.82M | 20.35M | 15.66M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 266.61M | 219.71M | 142.42M | 82.47M | 29.78M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 334.70M | 322.14M | 309.31M | 267.15M | 305.81M | 266.61M | 219.71M | 142.42M | 82.47M | 29.78M | 18.83M | 14.09M |
| Other Expenses | 246.00K | 511.00K | -814.00K | -495.00K | -697.00K | -1.16M | 1.07M | -1.10M | -1.74M | -1.88M | -654.00K | 186.00K |
| Operating Expenses | 389.37M | 375.20M | 356.98M | 312.75M | 364.83M | 315.07M | 257.27M | 176.15M | 103.85M | 49.60M | 39.18M | 29.75M |
| Cost & Expenses | 524.48M | 505.20M | 477.84M | 424.90M | 486.73M | 429.03M | 356.25M | 251.59M | 131.97M | 60.88M | 48.65M | 37.28M |
| Interest Income | 14.17M | 4.02M | 671.00K | 2.96M | 6.02M | 4.87M | 3.16M | 1.69M | 575.00K | 0.00 | 153.00K | 139.00K |
| Interest Expense | 8.01M | 6.43M | 19.75M | 21.81M | 10.93M | 10.40M | 9.90M | 6.39M | 2.73M | 16.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 11.54M | 10.33M | 8.68M | 8.19M | 7.80M | 3.89M | 2.51M | 1.72M | 614.00K | 96.00K | 47.00K | 39.00K |
| EBITDA | -78.31M | 21.02M | -102.40M | -52.21M | -83.36M | -37.86M | -22.84M | -22.04M | -62.92M | -30.09M | -25.10M | -19.09M |
| EBITDA Ratio | -18.42% | -50.16% | -18.33% | -17.36% | -24.72% | -10.78% | -9.05% | -9.55% | -89.60% | -86.90% | -106.83% | -105.18% |
| Operating Income | -99.31M | -98.84M | -90.93M | -62.85M | -96.48M | -41.74M | -29.58M | -23.08M | -62.37M | -28.31M | -25.15M | -19.13M |
| Operating Income Ratio | -23.36% | -24.32% | -23.50% | -17.36% | -24.72% | -10.78% | -9.05% | -10.10% | -89.60% | -86.90% | -107.03% | -105.40% |
| Total Other Income/Expenses | 1.45M | -1.90M | -19.89M | -19.35M | -5.61M | -6.69M | -5.67M | -7.07M | -3.90M | -1.90M | -501.00K | 325.00K |
| Income Before Tax | -97.86M | 4.26M | -130.83M | -82.20M | -102.09M | -48.44M | -35.25M | -30.16M | -66.27M | -30.20M | -25.65M | -18.81M |
| Income Before Tax Ratio | -23.02% | 1.05% | -33.81% | -22.70% | -26.16% | -12.51% | -10.79% | -13.20% | -95.20% | -92.72% | -109.16% | -103.61% |
| Income Tax Expense | -5.65M | 1.26M | 534.00K | 868.00K | 1.60M | 768.00K | 1.41M | 1.62M | 1.17M | 478.00K | 362.00K | 162.00K |
| Net Income | -92.21M | 3.00M | -131.36M | -83.07M | -103.69M | -49.21M | -36.66M | -31.78M | -67.43M | -30.68M | -26.01M | -18.97M |
| Net Income Ratio | -21.69% | 0.74% | -33.95% | -22.94% | -26.57% | -12.70% | -11.22% | -13.91% | -96.88% | -94.19% | -110.70% | -104.50% |
| EPS | -2.56 | 0.09 | -3.77 | -2.47 | -3.37 | -1.64 | -1.25 | -1.12 | -2.54 | -6.91 | -38.27 | -27.90 |
| EPS Diluted | -2.56 | 0.08 | -3.77 | -2.47 | -3.37 | -1.64 | -1.25 | -1.12 | -2.54 | -6.91 | -38.27 | -27.90 |
| Weighted Avg Shares Out | 35.98M | 35.32M | 34.82M | 33.68M | 30.80M | 30.05M | 29.42M | 28.49M | 26.58M | 4.44M | 679.77K | 679.77K |
| Weighted Avg Shares Out (Dil) | 35.98M | 35.53M | 34.82M | 33.68M | 30.80M | 30.05M | 29.42M | 28.49M | 26.58M | 4.44M | 679.77K | 679.77K |
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
REDWOOD CITY, Calif. , Aug. 14, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on August 7, 2024, the Compensation Committee of...
Nevro: Not Having My Back
Nevro Corp.'s shares hit fresh lows after revenue guidance reset, reflecting stagnant growth and substantial losses. The company has seen an eventful decade with huge share price fluctuations, but the situation is quite severe right now. Competitive pressures hurt the...
Nevro's (NVRO) Q2 Earnings Beat Estimates, Revenues Down Y/Y
Nevro's (NVRO) second-quarter earnings beat the Zacks Consensus Estimate while worldwide revenues decline year over over. The company incurs a loss at the operating level.
Nevro Corp. (NVRO) Q2 2024 Earnings Call Transcript
Nevro Corp. (NYSE:NVRO ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Angie McCabe - VP, IR & Corporate Communications Kevin Thornal - Chief Executive Officer & President Rod MacLeod - Chief Financial Officer Conference...
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
Nevro (NVRO) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.69 per share a year ago.
Nevro Reports Second-Quarter 2024 Financial Results
Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and Adjusted EBITDA Guidance to a Range of $(20) Million to $(18) Million...
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
REDWOOD CITY, Calif. , July 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on July 7, 2024, the Compensation Committee of...
Here's Why You Should Retain Nevro (NVRO) Stock for Now
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024
REDWOOD CITY, Calif. , July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the second...
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
REDWOOD CITY, Calif. , June 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on June 7, 2024, the Compensation Committee of the...
Source: https://incomestatements.info
Category: Stock Reports